TTI 200.7 / Pfizer - LARVOL DELTA

CD200 blocking antibody restores immune functions and reduces disease levels in preclinical acute myeloid leukaemia models (BSH 2019) - "Next we studied the effect of TTI-CD200 in the presence of CIK cells in mice, minimally engrafted with human AML cells, to model residual disease levels. Initial data showed significant reduction in disease levels upon TTI-CD200 (20mg/kg BW) treatment as compared to isotype control (0.005% vs 0.162%, p=0.028).In this study blocking CD200-CD200R interaction with a human CD200 blocking antibody was able to recover a significant proportion of AML patient immune activity, suggesting CD200 could be an effective therapeutic target for CD200+ AML in the context of MRD.DOI: The authors in this study have used CD200 blocking antibody developed by Trillium Therapeutics Inc."

IO Biomarker • Preclinical